They Sold Menopause Relief to Millions. The FDA Never Approved It. One Woman Bought It 50 Times.

The Product Every Pharmacy Sold. The Approval That Never Existed.

Walk into any CVS, Walgreens, or Target. Look for the menopause aisle. You will find Estroven. The purple box. The yellow box. “Mood Boost.” “Stress Relief.” “#1 Brand of Choice Among Women & Pharmacists,” the label says. Jaime Arnold found it in Sacramento. She bought it approximately 50 times between 2018 and 2022. She thought she was buying safe, effective menopause relief. She was buying unapproved drugs that violate federal law.

I-Health Inc., a wholly owned subsidiary of DSM Nutritional Products, Inc., manufactures and distributes Estroven. Both companies are Delaware corporations. I-Health operates out of Shelton, Connecticut. DSM’s principal place of business is Plainsboro, New Jersey. Neither company obtained FDA approval to market Estroven Mood Boost or Estroven Stress Relief as drugs. Both products make explicit efficacy claims for treating menopause symptoms. Under 21 U.S.C. § 355(a), that makes them unapproved new drugs. Introducing or delivering unapproved new drugs into interstate commerce is prohibited under 21 U.S.C. § 331(d).

The class action complaint, filed July 29, 2026, in the United States District Court for the Eastern District of California (Case 2:26-at-01282), alleges that I-Health and DSM violated multiple provisions of the Federal Food, Drug, and Cosmetic Act (FDCA), California Health & Safety Code § 111550, the California Unfair Competition Law (Bus. & Prof. Code §§ 17200 et seq.), and the California Consumer Legal Remedies Act (Civil Code §§ 1750 et seq.).

Jaime Arnold’s story is not unique. Estroven is sold nationally. The products are available on Amazon, at Walmart, at Target, and at independent pharmacies. The packaging claims the products “provide relief from hot flashes and night sweats,” “improve mood and support memory,” “manage stress and fatigue,” and “reduce the frequency and severity of hot flashes and night sweats.” The FDA never approved any of those claims.

“Estroven is formulated to provide relief from hot flashes and night sweats plus improve mood and support memory.” — Estroven Mood Boost product label (Exhibit 1, Arnold v. I-Health complaint)

The Ingredients That Don’t Work

Estroven Mood Boost and Estroven Stress Relief list the following as “active ingredients”: soy isoflavones, black cohosh root extract, ginkgo biloba leaf extract, and magnolia bark extract. The Arnold complaint cites multiple peer-reviewed scientific studies demonstrating that none of these ingredients, individually or in combination, safely and effectively treat menopause symptoms.

Soy Isoflavones

A 2024 systematic review and meta-analysis of 120 articles concluded that “soy isoflavones had no effect on menopausal symptoms (vasomotor, psychosocial, physical, sexual, and urogenital complaints) and quality of life in climacteric women.” (Nuran Gençtürk et al., 20 Explore 103012 (2024), cited at paragraph 31 of the complaint.)

A 2014 double-blind, randomized, placebo-controlled trial found that whole soy and soy isoflavone supplementation “have no significant effect on alleviation of menopausal symptoms.” (Zhao-Min Liu et al., 21 Menopause 653 (2014), cited at paragraph 32.)

A 2011 trial involving 248 participants found that the soy isoflavone group reported hot flashes at a significantly higher rate than the placebo group (48.4% vs 31.7%; P = .02). (Silvina Levis et al., 171 Archives of Internal Medicine 1363 (2011), cited at paragraph 33.)

A 2012 trial of 350 postmenopausal women concluded that “soy isoflavone supplementation in a dose comparable to that of traditional Asian diets has no effect on global cognition.” (Victor W. Henderson et al., 78 Neurology 1841 (2012), cited at paragraph 34.)

Black Cohosh Root Extract

The Merck Manual Professional Version states: “Data from several randomized trials do not support the efficacy of black cohosh for reducing menopausal symptoms.” (Laura Shane-McWhorter, Black Cohosh, Merck Manual Professional Version (July 2025), cited at paragraph 36.)

A Cochrane literature review of 16 randomized controlled trials involving 2,027 women found “no significant difference between black cohosh and placebo in the frequency of hot flushes… or in menopausal symptom scores.” The review also found that “hormone therapy significantly reduced daily hot flush frequency” compared to black cohosh. (Matthew J. Leach & Vivienne Moore, 2012 Cochrane Database of Systematic Reviews, Issue 9, Art. No. CD007244, cited at paragraph 37.)

Ginkgo Biloba

A 2003 trial examining the effects of ginkgo biloba on mood and cognition in postmenopausal women found “no significant effects of Gincosan treatment on ratings of mood, bodily symptoms of somatic anxiety, menopausal symptoms, or sleepiness or on any of the cognitive measures of attention, memory or frontal lobe function.” (D. Hartley et al., 7 Nutritional Neuroscience 325 (2003), cited at paragraph 39.)

Magnolia Bark Extract

A study examining magnolia bark extract’s effects on anxiety, stress, and sleep in healthy premenopausal women found it “was not effective in reducing long-standing feelings of anxiety or depression.” The study also found that “other assessments conducted in this study including salivary cortisol and amylase levels, appetite, body morphology and sleep quality/latency were not significantly changed by [Magnolia Bark] in comparison to placebo.” (Douglas S. Kalman et al., 7 Nutrition Journal 11 (2008), cited at paragraph 41.)

The complaint’s summary is blunt: “None of these ingredients, either individually or in combination, safely and effectively relieves menopause symptoms.” (Paragraph 28.)

The Non-Financial Ledger

Jaime Arnold made approximately 50 purchases. Each purchase was a transaction rooted in trust. She trusted the label. She trusted the “#1 Brand of Choice” claim. She trusted that a product sold in every major pharmacy, marketed as “safe, estrogen & drug free,” had been vetted by someone, somewhere, in the federal regulatory apparatus. That trust was misplaced.

Menopause is not a trivial condition. Hot flashes, night sweats, mood swings, anxiety, and sleeplessness are not cosmetic inconveniences. They are symptoms that disrupt daily life, relationships, and professional function. Women experiencing these symptoms are not hypochondriacs seeking placebos. They are patients seeking relief. When I-Health and DSM marketed Estroven as a solution, they entered the patient-treatment relationship. They made a promise. The promise was false.

The complaint does not quantify Jaime Arnold’s total expenditure across 50 purchases, but Estroven products retail between $13.99 and $18.99 per box. Assume a conservative average of $16 per purchase. That totals $800. $800 spent on products that do not work and were never approved by the FDA. $800 that could have funded co-pays for FDA-approved hormone replacement therapy, cognitive behavioral therapy for menopausal insomnia, or any other evidence-based intervention. Instead, it funded corporate revenue for products the law prohibits.

The loss is not merely financial. Arnold used Estroven “as directed.” She followed the dosage instructions. She waited for the promised relief. When relief did not materialize, what was her conclusion? That her symptoms were untreatable? That menopause was simply something she had to endure? Or did she continue purchasing, assuming that the next box, the next month, would finally deliver the results the label promised?

The complaint describes Arnold as having “suffered economic injury when she purchased Estroven because the product was not safe and effective for its intended purposes and was sold in violation of federal regulations and California law.” (Paragraph 96.) That sentence is legally precise. It is also an understatement. The injury is the theft of autonomy. The injury is the substitution of a corporate marketing claim for informed medical decision-making.

“Plaintiff used Estroven as directed, but the product was not satisfactory because it was an unlawful new drug, with an unlawful label, and because it does not effectively treat menopause symptoms.” — Arnold v. I-Health complaint, paragraph 14

Legal Receipts

The Arnold complaint does not rest on inference. It does not rely on consumer testimony or anecdotal claims. It cites the product labels. It cites the company website. It cites peer-reviewed scientific literature. It cites FDA warning letters to other companies making similar claims. The evidence is documentary. The violations are explicit.

These are not structure/function claims permissible under the Dietary Supplement Health and Education Act (DSHEA). These are drug claims. Under 21 U.S.C. § 321(g)(1)(B), a “drug” is defined as any article “intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.” Under 21 U.S.C. § 321(g)(1)(C), a “drug” is also any article “intended to affect the structure or any function of the body.” Estroven’s labeling explicitly claims the product treats menopause symptoms (hot flashes, night sweats, mood swings, anxiety). Those are disease claims. That makes Estroven a drug.

A “new drug” is defined under 21 U.S.C. § 321(p)(1) as any drug “not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the condition prescribed, recommended, or suggested in the labeling thereof.” The scientific literature establishes that Estroven’s ingredients are not generally recognized as safe and effective for treating menopause symptoms. That makes Estroven a new drug.

21 U.S.C. § 355(a) prohibits the introduction or delivery for introduction into interstate commerce of any new drug without an approved application from the FDA. I-Health and DSM have no such approval. That makes the sale of Estroven illegal under federal law.

California Health & Safety Code § 111550 adopts the federal prohibition. California also prohibits the sale of misbranded drugs under Health & Safety Code § 111440, § 111445, and § 111450. The complaint alleges Estroven is misbranded because its labeling is false and misleading (Health & Safety Code § 111330) and because it lacks adequate directions for safe use (21 U.S.C. § 352(f)(1)).

The complaint also alleges that Estroven’s disclaimer—”These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease”—is improperly placed in violation of 21 C.F.R. § 101.93(d). The regulation requires that the disclaimer “appear on each panel or page where there such is a statement.” Estroven’s efficacy claims appear on the front panel of the box. The disclaimer appears only on the back panel. That violates the regulation.

The complaint includes two FDA warning letters as exhibits. Exhibit 5 is a warning letter to AnuMed International, LLC, dated August 20, 2024. Exhibit 6 is a warning letter to Sambrosa Care Inc., dated January 24, 2024. Both letters cite similar violations: unapproved new drug claims, misbranding, and labeling that misleadingly suggests FDA approval. The FDA determined that claims such as “Relieves Menopause Symptoms,” “may help with menopause symptoms,” and “for Menopause Relief, Mood Swings, Hot Flashes” constitute drug claims requiring FDA approval. (Paragraph 69.)

I-Health and DSM’s conduct is not an isolated regulatory misstep. It is a business model.

Societal Impact Mapping

Public Health

The FDA’s policy on unapproved drugs is clear: “Unapproved prescription drugs pose significant risks to patients because they have not been reviewed by FDA for safety, effectiveness or quality.” (Paragraph 21, citing FDA guidance.) The policy continues: “Without FDA review, there is no way to know if these drugs are safe and effective for their intended use, whether they are manufactured in a way that ensures consistent drug quality or whether their label is complete and accurate.” (Paragraph 22.)

Consumers using unapproved drugs run the risk of “unexpected and undocumented safety concerns due to lack of rigorous pre- and postmarket safety surveillance.” (Paragraph 25.) They also forgo “medically proven therapies” (paragraph 26). When a woman purchases Estroven instead of seeking FDA-approved hormone replacement therapy or evidence-based cognitive behavioral therapy for insomnia, she is not making an informed choice between two legitimate treatment options. She is being diverted from effective care by false advertising.

The public health harm is not speculative. Menopause affects approximately 1.3 million American women each year. The market for menopause symptom relief is estimated in the hundreds of millions of dollars. If even 10% of that market is captured by unapproved products making false efficacy claims, the result is millions of women receiving ineffective treatment and delaying or avoiding effective care.

Economic Inequality

Estroven is sold over the counter. It does not require a prescription. It does not require a doctor’s visit. That makes it accessible to women who lack health insurance, who cannot afford specialist co-pays, or who live in areas with limited access to gynecologists or menopause clinics. The product is marketed as a low-cost alternative to prescription hormone therapy. For women with limited resources, that marketing is particularly coercive.

If you can afford a $150 telemedicine consultation with a menopause specialist, you can get a prescription for FDA-approved hormone therapy. If you cannot, you go to Target and buy the purple box. The purple box costs $16. It does not work. You buy it again next month. And the month after that. Over four years, Jaime Arnold made approximately 50 purchases. That is $800. $800 is a significant expenditure for a household at or below the median income. $800 spent on a product that was never legal and never effective.

The economic harm is not limited to the purchase price. There is also the opportunity cost. The $800 could have funded co-pays for effective care. It could have funded a gym membership, a meditation app subscription, or a sleep study—all interventions with evidence bases for managing menopause symptoms or comorbid conditions. Instead, it funded corporate revenue for an unapproved drug.

Environmental Degradation

This case does not involve direct environmental harm. However, the regulatory framework violated by I-Health and DSM is part of the same statutory architecture that governs drug manufacturing waste, pharmaceutical contamination of water supplies, and the environmental impact of active pharmaceutical ingredients. When companies are permitted to bypass FDA approval, they also bypass the environmental review and manufacturing oversight that accompany the new drug application process.

The broader implication is the erosion of regulatory authority. If the FDA cannot enforce the prohibition on unapproved new drugs in the consumer supplement market, its authority to enforce environmental compliance in pharmaceutical manufacturing is similarly weakened. The legal violations are fungible. The institutional damage is cumulative.

The “Cost of a Life” Metric

What Now?

The complaint identifies I-Health Inc. as a wholly owned subsidiary of DSM Nutritional Products, Inc. I-Health’s principal place of business is Shelton, Connecticut. DSM’s principal place of business is Plainsboro, New Jersey. Neither company’s CEO or board members are named in the complaint. Under the doctrine of respondeat superior, both corporate entities are liable for the conduct of their agents and employees.

The class action seeks the following relief:

• An order certifying the class: “All citizens and residents of California who purchased Estroven in California for their own personal or household use, and not for resale, from January 1, 2019 to the present.” (Paragraph 100.)
• An order enjoining I-Health and DSM from continuing to market and sell Estroven as an unapproved new drug. (Paragraph 88.)
• An order requiring I-Health and DSM to conduct a corrective advertising campaign. (Paragraph 15, paragraph 88.)
• An order requiring I-Health and DSM to destroy all unlawful products and labeling. (Paragraph 15.)
• Restitution and damages for all class members. (Paragraph 15, paragraph 89.)
• An order requiring I-Health and DSM to disgorge all revenue obtained from the sale of Estroven. (Paragraph 89.)
• Costs, expenses, and attorneys’ fees. (Paragraph 15.)

The plaintiff does not demand a jury trial. The case is assigned to the United States District Court for the Eastern District of California. The case number is 2:26-at-01282. The complaint was filed on July 29, 2026.

Watchlist

If this case proceeds to class certification, the following regulatory and enforcement agencies are relevant:

• U.S. Food and Drug Administration (FDA): Office of Unapproved Drugs and Labeling Compliance, Center for Drug Evaluation and Research (CDER). The FDA has statutory authority to pursue seizure and injunction against unapproved new drugs under 21 U.S.C. § 332 and § 334.
• Federal Trade Commission (FTC): Bureau of Consumer Protection, Division of Advertising Practices. The FTC has authority over false advertising claims under 15 U.S.C. § 45 (FTC Act, Section 5).
• California Attorney General: Consumer Protection Section. The California AG has enforcement authority under the California Unfair Competition Law and the Consumer Legal Remedies Act.
• California Department of Public Health: Food and Drug Branch. CDPH enforces California Health & Safety Code § 111550 and related provisions of the Sherman Food, Drug, and Cosmetic Law.

Grassroots Resistance and Mutual Aid

If you purchased Estroven in California between January 1, 2019, and the present, you are a potential class member. You do not need to take action at this time. If the class is certified, you will receive notice. If you wish to contact plaintiff’s counsel, the complaint lists The Weston Firm, Gregory S. Weston, 402 W. Broadway, Suite 400, San Diego, CA 92101.

If you are currently using Estroven and wish to discontinue, consult your primary care physician or a menopause specialist. Do not discontinue any medication or supplement without medical guidance. If you cannot afford a specialist consultation, the North American Menopause Society (NAMS) maintains a directory of certified menopause practitioners, some of whom offer sliding-scale fees. Planned Parenthood health centers also provide menopause consultations on a sliding scale in many states.

If you are experiencing menopause symptoms and seeking evidence-based care, the following resources may be useful:

• FDA-Approved Hormone Therapy: Systemic estrogen therapy and estrogen-progestin therapy are FDA-approved for moderate to severe hot flashes and night sweats. They require a prescription.
• Cognitive Behavioral Therapy for Insomnia (CBT-I): Evidence-based non-pharmacological treatment for menopausal insomnia. Many therapists offer telehealth sessions.
• Selective Serotonin Reuptake Inhibitors (SSRIs): Low-dose paroxetine (Brisdelle) is FDA-approved for hot flashes in women who cannot take estrogen. It requires a prescription.
• Lifestyle Interventions: Aerobic exercise, weight management, and smoking cessation have evidence bases for reducing hot flash frequency and severity.

This is not medical advice. This is a list of evidence-based options to discuss with your physician.

The plaintiff’s counsel in this case is Gregory S. Weston of The Weston Firm, San Diego, California. The complaint was prepared with attention to the documentary record. If you are considering joining a class action or bringing an individual claim, prioritize attorneys who cite primary sources.